We have to be careful here. I think that this study was carried out based on the hypothesis that all of Europe's demands with regard to broadening the intellectual property regime in Canada would be met.
Normally, health is a matter of provincial jurisdiction, just like national drug insurance programs. Consequently and first and foremost, the provinces are the ones that will have to deal with the cost increase. However, by tabling an agreement in principle in connection with the free trade agreement, the federal government committed to offering compensation to the provinces for the cost increases caused by certain provisions in CETA. In this way, this is no longer an obstacle for the provinces.
I am both a Quebec and Canadian taxpayer. This money will come out of my pocket one way or another. I am very conservative on tax matters. If the money is coming out of my pocket, I want it to be of benefit to me. However, that is not the case. Sixty per cent of Canadians have private insurance, but some, among the most vulnerable, have no insurance at all. Not only will they be subject to an increase in the cost of their drugs because of provisions in CETA, but they will receive no other benefit to compensate. This situation seems very problematic to me.